nodes	percent_of_prediction	percent_of_DWPC	metapath
Tafluprost—PTGS2—urinary bladder cancer	0.746	1	CbGaD
Tafluprost—PTGS2—Cisplatin—urinary bladder cancer	0.106	0.504	CbGbCtD
Tafluprost—PTGS2—Etoposide—urinary bladder cancer	0.104	0.496	CbGbCtD
Tafluprost—PTGFR—prostate gland—urinary bladder cancer	0.0071	0.204	CbGeAlD
Tafluprost—PTGFR—smooth muscle tissue—urinary bladder cancer	0.00502	0.145	CbGeAlD
Tafluprost—PTGFR—urethra—urinary bladder cancer	0.00475	0.137	CbGeAlD
Tafluprost—Dinoprost Tromethamine—HPGDS—urinary bladder cancer	0.00454	1	CrCbGaD
Tafluprost—PTGFR—female reproductive system—urinary bladder cancer	0.00387	0.112	CbGeAlD
Tafluprost—PTGFR—lymph node—urinary bladder cancer	0.00227	0.0653	CbGeAlD
Tafluprost—PTGS2—prostate gland—urinary bladder cancer	0.00195	0.0562	CbGeAlD
Tafluprost—PTGS2—seminal vesicle—urinary bladder cancer	0.00165	0.0475	CbGeAlD
Tafluprost—PTGS2—epithelium—urinary bladder cancer	0.00143	0.0413	CbGeAlD
Tafluprost—PTGS2—smooth muscle tissue—urinary bladder cancer	0.00138	0.0398	CbGeAlD
Tafluprost—PTGS2—renal system—urinary bladder cancer	0.00133	0.0383	CbGeAlD
Tafluprost—PTGS2—urethra—urinary bladder cancer	0.00131	0.0376	CbGeAlD
Tafluprost—PTGS2—female reproductive system—urinary bladder cancer	0.00106	0.0307	CbGeAlD
Tafluprost—PTGS2—vagina—urinary bladder cancer	0.000963	0.0277	CbGeAlD
Tafluprost—PTGS2—lymph node—urinary bladder cancer	0.000623	0.0179	CbGeAlD
Tafluprost—Common cold—Fluorouracil—urinary bladder cancer	0.000477	0.106	CcSEcCtD
Tafluprost—Urinary tract infection—Valrubicin—urinary bladder cancer	0.000236	0.0524	CcSEcCtD
Tafluprost—Cataract—Thiotepa—urinary bladder cancer	0.000158	0.0351	CcSEcCtD
Tafluprost—Eye irritation—Fluorouracil—urinary bladder cancer	0.000146	0.0324	CcSEcCtD
Tafluprost—Photophobia—Thiotepa—urinary bladder cancer	0.000141	0.0314	CcSEcCtD
Tafluprost—Lacrimation increased—Fluorouracil—urinary bladder cancer	0.000135	0.03	CcSEcCtD
Tafluprost—Vision blurred—Mitomycin—urinary bladder cancer	0.000123	0.0274	CcSEcCtD
Tafluprost—Photophobia—Fluorouracil—urinary bladder cancer	0.000117	0.0259	CcSEcCtD
Tafluprost—Cough—Mitomycin—urinary bladder cancer	0.000114	0.0253	CcSEcCtD
Tafluprost—Pruritus—Valrubicin—urinary bladder cancer	0.00011	0.0243	CcSEcCtD
Tafluprost—Headache—Valrubicin—urinary bladder cancer	9.72e-05	0.0215	CcSEcCtD
Tafluprost—Dyspnoea—Mitomycin—urinary bladder cancer	9.53e-05	0.0211	CcSEcCtD
Tafluprost—Nasopharyngitis—Fluorouracil—urinary bladder cancer	8.09e-05	0.0179	CcSEcCtD
Tafluprost—Nasopharyngitis—Cisplatin—urinary bladder cancer	7.67e-05	0.017	CcSEcCtD
Tafluprost—Eye disorder—Thiotepa—urinary bladder cancer	7.07e-05	0.0157	CcSEcCtD
Tafluprost—Urinary tract infection—Fluorouracil—urinary bladder cancer	6.78e-05	0.015	CcSEcCtD
Tafluprost—Headache—Mitomycin—urinary bladder cancer	6.7e-05	0.0148	CcSEcCtD
Tafluprost—Lacrimation increased—Epirubicin—urinary bladder cancer	6.58e-05	0.0146	CcSEcCtD
Tafluprost—Rhinitis—Gemcitabine—urinary bladder cancer	6.38e-05	0.0141	CcSEcCtD
Tafluprost—Rhinitis—Fluorouracil—urinary bladder cancer	6.27e-05	0.0139	CcSEcCtD
Tafluprost—Vision blurred—Thiotepa—urinary bladder cancer	6.21e-05	0.0138	CcSEcCtD
Tafluprost—Lacrimation increased—Doxorubicin—urinary bladder cancer	6.09e-05	0.0135	CcSEcCtD
Tafluprost—Cough—Thiotepa—urinary bladder cancer	5.75e-05	0.0127	CcSEcCtD
Tafluprost—Dry eye—Epirubicin—urinary bladder cancer	5.6e-05	0.0124	CcSEcCtD
Tafluprost—Eye disorder—Cisplatin—urinary bladder cancer	5.54e-05	0.0123	CcSEcCtD
Tafluprost—Nervous system disorder—Thiotepa—urinary bladder cancer	5.27e-05	0.0117	CcSEcCtD
Tafluprost—Dry eye—Doxorubicin—urinary bladder cancer	5.18e-05	0.0115	CcSEcCtD
Tafluprost—Vision blurred—Fluorouracil—urinary bladder cancer	5.13e-05	0.0114	CcSEcCtD
Tafluprost—Eye disorder—Etoposide—urinary bladder cancer	5.08e-05	0.0113	CcSEcCtD
Tafluprost—Eye pain—Epirubicin—urinary bladder cancer	4.88e-05	0.0108	CcSEcCtD
Tafluprost—Vision blurred—Cisplatin—urinary bladder cancer	4.87e-05	0.0108	CcSEcCtD
Tafluprost—Cough—Gemcitabine—urinary bladder cancer	4.83e-05	0.0107	CcSEcCtD
Tafluprost—Eye pain—Doxorubicin—urinary bladder cancer	4.51e-05	0.01	CcSEcCtD
Tafluprost—Nervous system disorder—Gemcitabine—urinary bladder cancer	4.43e-05	0.00983	CcSEcCtD
Tafluprost—Nervous system disorder—Fluorouracil—urinary bladder cancer	4.36e-05	0.00967	CcSEcCtD
Tafluprost—Nervous system disorder—Cisplatin—urinary bladder cancer	4.13e-05	0.00916	CcSEcCtD
Tafluprost—Cough—Etoposide—urinary bladder cancer	4.13e-05	0.00915	CcSEcCtD
Tafluprost—Asthma—Methotrexate—urinary bladder cancer	4.07e-05	0.00902	CcSEcCtD
Tafluprost—PTGS2—Synthesis of 15-eicosatetraenoic acid derivatives—GPX1—urinary bladder cancer	4.04e-05	0.0696	CbGpPWpGaD
Tafluprost—Dyspnoea—Gemcitabine—urinary bladder cancer	4.03e-05	0.00894	CcSEcCtD
Tafluprost—Dyspnoea—Fluorouracil—urinary bladder cancer	3.96e-05	0.00879	CcSEcCtD
Tafluprost—Nasopharyngitis—Epirubicin—urinary bladder cancer	3.94e-05	0.00873	CcSEcCtD
Tafluprost—Asthma—Epirubicin—urinary bladder cancer	3.81e-05	0.00844	CcSEcCtD
Tafluprost—Pruritus—Thiotepa—urinary bladder cancer	3.8e-05	0.00843	CcSEcCtD
Tafluprost—Dyspnoea—Cisplatin—urinary bladder cancer	3.76e-05	0.00833	CcSEcCtD
Tafluprost—Nasopharyngitis—Doxorubicin—urinary bladder cancer	3.64e-05	0.00808	CcSEcCtD
Tafluprost—Asthma—Doxorubicin—urinary bladder cancer	3.52e-05	0.00781	CcSEcCtD
Tafluprost—PTGS2—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—HPGDS—urinary bladder cancer	3.47e-05	0.0597	CbGpPWpGaD
Tafluprost—Dyspnoea—Etoposide—urinary bladder cancer	3.44e-05	0.00763	CcSEcCtD
Tafluprost—Headache—Thiotepa—urinary bladder cancer	3.37e-05	0.00746	CcSEcCtD
Tafluprost—Urinary tract infection—Epirubicin—urinary bladder cancer	3.3e-05	0.00731	CcSEcCtD
Tafluprost—Pruritus—Gemcitabine—urinary bladder cancer	3.2e-05	0.00709	CcSEcCtD
Tafluprost—Pruritus—Fluorouracil—urinary bladder cancer	3.15e-05	0.00697	CcSEcCtD
Tafluprost—Rhinitis—Epirubicin—urinary bladder cancer	3.05e-05	0.00677	CcSEcCtD
Tafluprost—Urinary tract infection—Doxorubicin—urinary bladder cancer	3.05e-05	0.00677	CcSEcCtD
Tafluprost—Eye disorder—Methotrexate—urinary bladder cancer	3.04e-05	0.00674	CcSEcCtD
Tafluprost—Eye disorder—Epirubicin—urinary bladder cancer	2.85e-05	0.00631	CcSEcCtD
Tafluprost—Headache—Gemcitabine—urinary bladder cancer	2.83e-05	0.00628	CcSEcCtD
Tafluprost—Rhinitis—Doxorubicin—urinary bladder cancer	2.83e-05	0.00626	CcSEcCtD
Tafluprost—Headache—Fluorouracil—urinary bladder cancer	2.79e-05	0.00617	CcSEcCtD
Tafluprost—Pruritus—Etoposide—urinary bladder cancer	2.73e-05	0.00606	CcSEcCtD
Tafluprost—Vision blurred—Methotrexate—urinary bladder cancer	2.67e-05	0.00592	CcSEcCtD
Tafluprost—Eye disorder—Doxorubicin—urinary bladder cancer	2.63e-05	0.00584	CcSEcCtD
Tafluprost—Vision blurred—Epirubicin—urinary bladder cancer	2.5e-05	0.00554	CcSEcCtD
Tafluprost—Cough—Methotrexate—urinary bladder cancer	2.47e-05	0.00548	CcSEcCtD
Tafluprost—Headache—Etoposide—urinary bladder cancer	2.42e-05	0.00536	CcSEcCtD
Tafluprost—PTGS2—Arachidonic acid metabolism—CYP4B1—urinary bladder cancer	2.36e-05	0.0405	CbGpPWpGaD
Tafluprost—Cough—Epirubicin—urinary bladder cancer	2.31e-05	0.00513	CcSEcCtD
Tafluprost—Vision blurred—Doxorubicin—urinary bladder cancer	2.31e-05	0.00513	CcSEcCtD
Tafluprost—Nervous system disorder—Methotrexate—urinary bladder cancer	2.27e-05	0.00503	CcSEcCtD
Tafluprost—Cough—Doxorubicin—urinary bladder cancer	2.14e-05	0.00475	CcSEcCtD
Tafluprost—Nervous system disorder—Epirubicin—urinary bladder cancer	2.12e-05	0.00471	CcSEcCtD
Tafluprost—Dyspnoea—Methotrexate—urinary bladder cancer	2.06e-05	0.00457	CcSEcCtD
Tafluprost—PTGFR—Prostaglandin Synthesis and Regulation—PTGS2—urinary bladder cancer	2.01e-05	0.0346	CbGpPWpGaD
Tafluprost—Nervous system disorder—Doxorubicin—urinary bladder cancer	1.96e-05	0.00435	CcSEcCtD
Tafluprost—Dyspnoea—Epirubicin—urinary bladder cancer	1.93e-05	0.00428	CcSEcCtD
Tafluprost—PTGS2—C-MYB transcription factor network—PTCRA—urinary bladder cancer	1.89e-05	0.0325	CbGpPWpGaD
Tafluprost—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—GSTO2—urinary bladder cancer	1.84e-05	0.0316	CbGpPWpGaD
Tafluprost—Dyspnoea—Doxorubicin—urinary bladder cancer	1.79e-05	0.00396	CcSEcCtD
Tafluprost—Pruritus—Methotrexate—urinary bladder cancer	1.64e-05	0.00363	CcSEcCtD
Tafluprost—Pruritus—Epirubicin—urinary bladder cancer	1.53e-05	0.00339	CcSEcCtD
Tafluprost—Headache—Methotrexate—urinary bladder cancer	1.45e-05	0.00321	CcSEcCtD
Tafluprost—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—SLC19A1—urinary bladder cancer	1.43e-05	0.0246	CbGpPWpGaD
Tafluprost—Pruritus—Doxorubicin—urinary bladder cancer	1.42e-05	0.00314	CcSEcCtD
Tafluprost—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—PRSS3—urinary bladder cancer	1.39e-05	0.024	CbGpPWpGaD
Tafluprost—Headache—Epirubicin—urinary bladder cancer	1.36e-05	0.00301	CcSEcCtD
Tafluprost—PTGS2—Aryl Hydrocarbon Receptor—HPGDS—urinary bladder cancer	1.34e-05	0.0231	CbGpPWpGaD
Tafluprost—Headache—Doxorubicin—urinary bladder cancer	1.25e-05	0.00278	CcSEcCtD
Tafluprost—PTGS2—Arachidonic acid metabolism—HPGDS—urinary bladder cancer	1.25e-05	0.0216	CbGpPWpGaD
Tafluprost—PTGS2—Aryl Hydrocarbon Receptor—NQO1—urinary bladder cancer	1.08e-05	0.0186	CbGpPWpGaD
Tafluprost—PTGS2—S1P1 pathway—RHOA—urinary bladder cancer	1.05e-05	0.018	CbGpPWpGaD
Tafluprost—PTGS2—C-MYB transcription factor network—BIRC3—urinary bladder cancer	9.55e-06	0.0164	CbGpPWpGaD
Tafluprost—PTGS2—Overview of nanoparticle effects—CXCL8—urinary bladder cancer	9.18e-06	0.0158	CbGpPWpGaD
Tafluprost—PTGS2—C-MYB transcription factor network—MPO—urinary bladder cancer	8.17e-06	0.0141	CbGpPWpGaD
Tafluprost—PTGS2—Signaling mediated by p38-alpha and p38-beta—ESR1—urinary bladder cancer	8.09e-06	0.0139	CbGpPWpGaD
Tafluprost—PTGS2—Selenium Micronutrient Network—MPO—urinary bladder cancer	7.87e-06	0.0136	CbGpPWpGaD
Tafluprost—PTGS2—Arachidonic acid metabolism—GPX1—urinary bladder cancer	7.41e-06	0.0128	CbGpPWpGaD
Tafluprost—PTGS2—Aryl Hydrocarbon Receptor—ESR1—urinary bladder cancer	6.5e-06	0.0112	CbGpPWpGaD
Tafluprost—PTGS2—Overview of nanoparticle effects—TNF—urinary bladder cancer	6.39e-06	0.011	CbGpPWpGaD
Tafluprost—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL2—urinary bladder cancer	6.26e-06	0.0108	CbGpPWpGaD
Tafluprost—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CDK4—urinary bladder cancer	6.11e-06	0.0105	CbGpPWpGaD
Tafluprost—PTGS2—Aryl Hydrocarbon Receptor—RB1—urinary bladder cancer	5.68e-06	0.00977	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—LIG1—urinary bladder cancer	5.62e-06	0.00968	CbGpPWpGaD
Tafluprost—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PPARG—urinary bladder cancer	5.55e-06	0.00955	CbGpPWpGaD
Tafluprost—PTGS2—C-MYB transcription factor network—NCOR1—urinary bladder cancer	5.11e-06	0.0088	CbGpPWpGaD
Tafluprost—PTGS2—C-MYB transcription factor network—GSTM1—urinary bladder cancer	5.11e-06	0.0088	CbGpPWpGaD
Tafluprost—PTGS2—Selenium Micronutrient Network—SOD2—urinary bladder cancer	4.94e-06	0.00851	CbGpPWpGaD
Tafluprost—PTGS2—Selenium Micronutrient Network—GPX1—urinary bladder cancer	4.72e-06	0.00812	CbGpPWpGaD
Tafluprost—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—MTHFR—urinary bladder cancer	4.39e-06	0.00756	CbGpPWpGaD
Tafluprost—PTGS2—Selenium Micronutrient Network—MTHFR—urinary bladder cancer	4.35e-06	0.00749	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—HPGDS—urinary bladder cancer	4.29e-06	0.00738	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—IGFBP3—urinary bladder cancer	4.26e-06	0.00734	CbGpPWpGaD
Tafluprost—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CXCL8—urinary bladder cancer	4.23e-06	0.00729	CbGpPWpGaD
Tafluprost—PTGS2—Aryl Hydrocarbon Receptor—CDKN1A—urinary bladder cancer	4.08e-06	0.00702	CbGpPWpGaD
Tafluprost—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—urinary bladder cancer	4.05e-06	0.00696	CbGpPWpGaD
Tafluprost—PTGS2—Aryl Hydrocarbon Receptor—EP300—urinary bladder cancer	3.88e-06	0.00668	CbGpPWpGaD
Tafluprost—PTGS2—Aryl Hydrocarbon Receptor—SRC—urinary bladder cancer	3.77e-06	0.00649	CbGpPWpGaD
Tafluprost—PTGS2—C-MYB transcription factor network—CREBBP—urinary bladder cancer	3.52e-06	0.00606	CbGpPWpGaD
Tafluprost—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—urinary bladder cancer	3.46e-06	0.00595	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—ESR2—urinary bladder cancer	3.43e-06	0.00591	CbGpPWpGaD
Tafluprost—PTGS2—Aryl Hydrocarbon Receptor—MYC—urinary bladder cancer	3.38e-06	0.00582	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—HDAC4—urinary bladder cancer	3.37e-06	0.00581	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	3.37e-06	0.00579	CbGpPWpGaD
Tafluprost—PTGS2—Aryl Hydrocarbon Receptor—EGFR—urinary bladder cancer	3.31e-06	0.00569	CbGpPWpGaD
Tafluprost—PTGS2—Aryl Hydrocarbon Receptor—TNF—urinary bladder cancer	3.15e-06	0.00542	CbGpPWpGaD
Tafluprost—PTGS2—Aryl Hydrocarbon Receptor—KRAS—urinary bladder cancer	3.12e-06	0.00538	CbGpPWpGaD
Tafluprost—PTGS2—C-MYB transcription factor network—CDKN2A—urinary bladder cancer	3.08e-06	0.0053	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—CDK4—urinary bladder cancer	3.07e-06	0.00529	CbGpPWpGaD
Tafluprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	2.99e-06	0.00515	CbGpPWpGaD
Tafluprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—urinary bladder cancer	2.95e-06	0.00508	CbGpPWpGaD
Tafluprost—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—urinary bladder cancer	2.95e-06	0.00507	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—GLI1—urinary bladder cancer	2.83e-06	0.00487	CbGpPWpGaD
Tafluprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—urinary bladder cancer	2.79e-06	0.0048	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—CCNE1—urinary bladder cancer	2.73e-06	0.0047	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—TYMS—urinary bladder cancer	2.68e-06	0.00461	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—RB1—urinary bladder cancer	2.67e-06	0.0046	CbGpPWpGaD
Tafluprost—PTGS2—Aryl Hydrocarbon Receptor—HRAS—urinary bladder cancer	2.66e-06	0.00457	CbGpPWpGaD
Tafluprost—PTGS2—C-MYB transcription factor network—CCND1—urinary bladder cancer	2.6e-06	0.00448	CbGpPWpGaD
Tafluprost—PTGS2—C-MYB transcription factor network—CDKN1A—urinary bladder cancer	2.52e-06	0.00434	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—RHOA—urinary bladder cancer	2.43e-06	0.00418	CbGpPWpGaD
Tafluprost—PTGS2—C-MYB transcription factor network—EP300—urinary bladder cancer	2.4e-06	0.00413	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	2.38e-06	0.00409	CbGpPWpGaD
Tafluprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—urinary bladder cancer	2.37e-06	0.00408	CbGpPWpGaD
Tafluprost—PTGFR—GPCR ligand binding—CXCL8—urinary bladder cancer	2.28e-06	0.00392	CbGpPWpGaD
Tafluprost—PTGS2—Disease—GSTO2—urinary bladder cancer	2.17e-06	0.00374	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—CXCL8—urinary bladder cancer	2.13e-06	0.00367	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	2.1e-06	0.00361	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	2.09e-06	0.0036	CbGpPWpGaD
Tafluprost—PTGS2—C-MYB transcription factor network—MYC—urinary bladder cancer	2.09e-06	0.00359	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	2.08e-06	0.00358	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—IL2—urinary bladder cancer	2.04e-06	0.0035	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—CCND1—urinary bladder cancer	1.98e-06	0.00341	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—RBX1—urinary bladder cancer	1.94e-06	0.00333	CbGpPWpGaD
Tafluprost—PTGS2—C-MYB transcription factor network—KRAS—urinary bladder cancer	1.93e-06	0.00332	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—MMP9—urinary bladder cancer	1.93e-06	0.00332	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—GSTZ1—urinary bladder cancer	1.92e-06	0.00331	CbGpPWpGaD
Tafluprost—PTGS2—Selenium Micronutrient Network—TNF—urinary bladder cancer	1.87e-06	0.00323	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	1.82e-06	0.00314	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—TSC1—urinary bladder cancer	1.82e-06	0.00314	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—GSTO2—urinary bladder cancer	1.82e-06	0.00313	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—NAT1—urinary bladder cancer	1.82e-06	0.00313	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	1.8e-06	0.0031	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	1.79e-06	0.00308	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—JAG1—urinary bladder cancer	1.73e-06	0.00298	CbGpPWpGaD
Tafluprost—PTGS2—Disease—SLC19A1—urinary bladder cancer	1.69e-06	0.00291	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—UGT2B7—urinary bladder cancer	1.67e-06	0.00287	CbGpPWpGaD
Tafluprost—PTGS2—Disease—PRSS3—urinary bladder cancer	1.65e-06	0.00284	CbGpPWpGaD
Tafluprost—PTGS2—C-MYB transcription factor network—HRAS—urinary bladder cancer	1.64e-06	0.00282	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—MYC—urinary bladder cancer	1.59e-06	0.00274	CbGpPWpGaD
Tafluprost—PTGS2—Disease—HDAC4—urinary bladder cancer	1.57e-06	0.00271	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—EGFR—urinary bladder cancer	1.56e-06	0.00268	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	1.53e-06	0.00263	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—CYP4B1—urinary bladder cancer	1.5e-06	0.00258	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—TNF—urinary bladder cancer	1.48e-06	0.00255	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—RHOA—urinary bladder cancer	1.47e-06	0.00252	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—SLC19A1—urinary bladder cancer	1.42e-06	0.00244	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—S100B—urinary bladder cancer	1.4e-06	0.00242	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—PRSS3—urinary bladder cancer	1.38e-06	0.00238	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	1.35e-06	0.00232	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—RHOA—urinary bladder cancer	1.33e-06	0.00229	CbGpPWpGaD
Tafluprost—PTGS2—Spinal Cord Injury—TP53—urinary bladder cancer	1.31e-06	0.00225	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	1.31e-06	0.00225	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	1.3e-06	0.00224	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—CXCL8—urinary bladder cancer	1.29e-06	0.00221	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—NCOR1—urinary bladder cancer	1.26e-06	0.00217	CbGpPWpGaD
Tafluprost—PTGS2—Disease—LIG1—urinary bladder cancer	1.25e-06	0.00215	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	1.24e-06	0.00214	CbGpPWpGaD
Tafluprost—PTGFR—GPCR downstream signaling—IL2—urinary bladder cancer	1.23e-06	0.00212	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	1.21e-06	0.00208	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—CXCL8—urinary bladder cancer	1.17e-06	0.00201	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—IL2—urinary bladder cancer	1.12e-06	0.00192	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—TERT—urinary bladder cancer	1.11e-06	0.00192	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	1.11e-06	0.0019	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—TYMP—urinary bladder cancer	1.1e-06	0.0019	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	1.08e-06	0.00186	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	1.06e-06	0.00182	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	1.06e-06	0.00182	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—FGFR3—urinary bladder cancer	1.02e-06	0.00176	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	1.01e-06	0.00174	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	1e-06	0.00172	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—NAT2—urinary bladder cancer	9.98e-07	0.00172	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—ESR1—urinary bladder cancer	9.92e-07	0.00171	CbGpPWpGaD
Tafluprost—PTGS2—Disease—ENO2—urinary bladder cancer	9.52e-07	0.00164	CbGpPWpGaD
Tafluprost—PTGS2—Disease—RBX1—urinary bladder cancer	9.03e-07	0.00155	CbGpPWpGaD
Tafluprost—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	8.89e-07	0.00153	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—CREBBP—urinary bladder cancer	8.69e-07	0.0015	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—RRM2—urinary bladder cancer	8.61e-07	0.00148	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—IGF1—urinary bladder cancer	8.58e-07	0.00148	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—EGFR—urinary bladder cancer	8.54e-07	0.00147	CbGpPWpGaD
Tafluprost—PTGS2—Disease—JAG1—urinary bladder cancer	8.08e-07	0.00139	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—KRAS—urinary bladder cancer	8.07e-07	0.00139	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—HPGDS—urinary bladder cancer	7.98e-07	0.00137	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—ENO2—urinary bladder cancer	7.98e-07	0.00137	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	7.93e-07	0.00136	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—RHOA—urinary bladder cancer	7.86e-07	0.00135	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—GSTT1—urinary bladder cancer	7.74e-07	0.00133	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	7.62e-07	0.00131	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—ERBB2—urinary bladder cancer	7.28e-07	0.00125	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—CXCL8—urinary bladder cancer	6.9e-07	0.00119	CbGpPWpGaD
Tafluprost—PTGFR—Signaling by GPCR—HRAS—urinary bladder cancer	6.86e-07	0.00118	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—IL2—urinary bladder cancer	6.6e-07	0.00114	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—CCND1—urinary bladder cancer	6.43e-07	0.00111	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—NQO1—urinary bladder cancer	6.43e-07	0.00111	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—MMP9—urinary bladder cancer	6.24e-07	0.00107	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—CDKN1A—urinary bladder cancer	6.22e-07	0.00107	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—PTEN—urinary bladder cancer	6.21e-07	0.00107	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—EP300—urinary bladder cancer	5.92e-07	0.00102	CbGpPWpGaD
Tafluprost—PTGS2—Disease—NCOR1—urinary bladder cancer	5.88e-07	0.00101	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—SRC—urinary bladder cancer	5.76e-07	0.000991	CbGpPWpGaD
Tafluprost—PTGS2—Disease—ERCC2—urinary bladder cancer	5.53e-07	0.000952	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	5.44e-07	0.000936	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—GSTP1—urinary bladder cancer	5.36e-07	0.000923	CbGpPWpGaD
Tafluprost—PTGS2—Disease—MTHFR—urinary bladder cancer	5.2e-07	0.000895	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	5.19e-07	0.000893	CbGpPWpGaD
Tafluprost—PTGS2—Disease—TERT—urinary bladder cancer	5.19e-07	0.000892	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—MYC—urinary bladder cancer	5.16e-07	0.000888	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—EGFR—urinary bladder cancer	5.05e-07	0.000868	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—TYMS—urinary bladder cancer	4.99e-07	0.000858	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—NCOR1—urinary bladder cancer	4.93e-07	0.000848	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—GSTM1—urinary bladder cancer	4.93e-07	0.000848	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—KRAS—urinary bladder cancer	4.77e-07	0.00082	CbGpPWpGaD
Tafluprost—PTGS2—Disease—FGFR3—urinary bladder cancer	4.76e-07	0.000819	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—GPX1—urinary bladder cancer	4.72e-07	0.000812	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—ERCC2—urinary bladder cancer	4.63e-07	0.000797	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—MTHFR—urinary bladder cancer	4.36e-07	0.000749	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—TP53—urinary bladder cancer	4.24e-07	0.000729	CbGpPWpGaD
Tafluprost—PTGFR—Signaling Pathways—HRAS—urinary bladder cancer	4.05e-07	0.000697	CbGpPWpGaD
Tafluprost—PTGS2—Disease—CREBBP—urinary bladder cancer	4.05e-07	0.000697	CbGpPWpGaD
Tafluprost—PTGS2—Disease—RHOA—urinary bladder cancer	3.66e-07	0.000631	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—PPARG—urinary bladder cancer	3.53e-07	0.000608	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—CREBBP—urinary bladder cancer	3.39e-07	0.000584	CbGpPWpGaD
Tafluprost—PTGS2—Disease—ERBB2—urinary bladder cancer	3.39e-07	0.000584	CbGpPWpGaD
Tafluprost—PTGS2—Disease—CDKN1A—urinary bladder cancer	2.9e-07	0.000499	CbGpPWpGaD
Tafluprost—PTGS2—Disease—PTEN—urinary bladder cancer	2.89e-07	0.000498	CbGpPWpGaD
Tafluprost—PTGS2—Disease—EP300—urinary bladder cancer	2.76e-07	0.000475	CbGpPWpGaD
Tafluprost—PTGS2—Disease—SRC—urinary bladder cancer	2.68e-07	0.000462	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—PTEN—urinary bladder cancer	2.42e-07	0.000417	CbGpPWpGaD
Tafluprost—PTGS2—Disease—MYC—urinary bladder cancer	2.4e-07	0.000414	CbGpPWpGaD
Tafluprost—PTGS2—Disease—EGFR—urinary bladder cancer	2.35e-07	0.000405	CbGpPWpGaD
Tafluprost—PTGS2—Metabolism—EP300—urinary bladder cancer	2.31e-07	0.000398	CbGpPWpGaD
Tafluprost—PTGS2—Disease—KRAS—urinary bladder cancer	2.22e-07	0.000382	CbGpPWpGaD
Tafluprost—PTGS2—Disease—HRAS—urinary bladder cancer	1.89e-07	0.000325	CbGpPWpGaD
